Loading video.
VIDEO: A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced. The vaccine showed success in stimulating production of. view more
Credit: Scripps Research
NEW YORK and LA JOLLA, CA A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine.
HIV antibody trial results offer proof of concept
Outcome of AMP shows feasibility of developing potent antibody combinations to block HIV March 17, 2021 • By Sabin Russell / Fred Hutch News Service Dr. Larry Corey, former president and director of Fred Hutchinson Cancer Research Center, was protocol chair of the Antibody Mediated Prevention trials and reported first results prior to the online HIV Research for Prevention scientific conference, which opened on Jan. 27. Photo by Robert Hood / Fred Hutch News Service
Editor s note: The story below was originally published on Jan. 26, 2021, upon release of the AMP results prior to an international HIV prevention conference. Details of the paired AMP trials have now been published in the March 18, 2021 edition of the
Shed the pandemic pounds . and the stupor
As vaccines roll out and the crisis ebbs, get more sleep, eat mostly plants, keep moving and stay connected January 22, 2021 • By Diane Mapes / Fred Hutch News Service Give your body a disease-busting boost of cruciferous vegetables. Brassicas like kale, cauliflower, bok choy, rutabaga, arugula, turnip and Brussels sprouts are heavy hitters, packed with nutrition and chemopreventive. Fred Hutch file photo
Join Dr. Heather Greenlee
a virtual researcher roundtable
Fred Hutch experts will share best practices to reduce risk of disease, get the exercise you need wherever you live, and stay healthy as we hunker down for the pandemic homestretch.
Building trust in safe and effective COVID-19 vaccines
Convincing millions to get vaccinated will take more than data, facts and figures January 21, 2021 • By Sabin Russell / Fred Hutch News Service Anthony Jackson, security coordinator for Fred Hutchinson Cancer Research Center, receives a dose of the new Pfizer-BioNTech COVID-19 vaccine on Jan. 19, 2021, at a new vaccine clinic set up on the Fred Hutch campus. Photo by Robert Hood / Fred Hutch News Service
On the morning of Dec. 29, as a historic and harrowing year was drawing to a close, Dr. Steven Pergam bared his left shoulder to receive his first dose of the COVID-19 vaccine.
Medexus Pharmaceuticals and medac GmbH enter into a License Agreement for First-in-Class Conditioning Agent for Hematopoietic Stem Cell Transplantation, Treosulfan, in the United States
February 02, 2021 14:21 ET | Source: Medexus Pharmaceuticals Inc Medexus Pharmaceuticals Inc
Orphan Designated Drug with August 2021 PDUFA date
Management to host conference call at 10:00 AM Eastern Time on February 3, 2021 and
Key Opinion Leader webinar to be held at 2:00 PM Eastern Time on February 5, 2021
TORONTO and CHICAGO and MONTREAL and WEDEL, Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) Medexus Pharmaceuticals Inc. (“
Medexus”) (TSXV: MDP) (OTCQX: MEDXF)
(Frankfurt: P731) is pleased to announce that it and its wholly-owned United States-based subsidiary, Medexus Pharma, Inc. (“